Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

5-HT(1B) receptors play a prominent role in the proliferation of T-lymphocytes.

Yin J, Albert RH, Tretiakova AP, Jameson BA.

J Neuroimmunol. 2006 Dec;181(1-2):68-81. Epub 2006 Oct 2.

PMID:
17011639
2.

New insights from the structure-function analysis of the catalytic region of human platelet phosphodiesterase 3A: a role for the unique 44-amino acid insert.

Hung SH, Zhang W, Pixley RA, Jameson BA, Huang YC, Colman RF, Colman RW.

J Biol Chem. 2006 Sep 29;281(39):29236-44. Epub 2006 Jul 27.

3.

A rational design approach for developing immunomodulators based on CD4 and CD8.

Tretiakova AP, Albert RH, Jameson BA.

Biotechnol Genet Eng Rev. 2002;19:175-203. Review. No abstract available.

PMID:
12520878
4.

Rational design of cytotoxic T-cell inhibitors.

Tretiakova AP, Little CS, Blank KJ, Jameson BA.

Nat Biotechnol. 2000 Sep;18(9):984-8.

PMID:
10973221
5.

Structure and function of procollagen C-proteinase (mTolloid) domains determined by protease digestion, circular dichroism, binding to procollagen type I, and computer modeling.

Sieron AL, Tretiakova A, Jameson BA, Segall ML, Lund-Katz S, Khan MT, Li Sw, Stöcker W.

Biochemistry. 2000 Mar 28;39(12):3231-9.

PMID:
10727214
6.
7.

A synthetic mimetic of CD4 is able to suppress disease in a rodent model of immune colitis.

Okamoto S, Watanabe M, Yamazaki M, Yajima T, Hayashi T, Ishii H, Mukai M, Yamada T, Watanabe N, Jameson BA, Hibi T.

Eur J Immunol. 1999 Jan;29(1):355-66.

8.
10.

Peptide analogs that inhibit IgE-Fc epsilon RI alpha interactions ameliorate the development of lethal graft-versus-host disease.

Korngold R, Jameson BA, McDonnell JM, Leighton C, Sutton BJ, Gould HJ, Murphy GF.

Biol Blood Marrow Transplant. 1997 Oct;3(4):187-93.

PMID:
9360780
11.
12.

Identification of a human CD4-CDR3-like surface involved in CD4+ T cell function.

Friedman TM, Reddy AP, Wassell R, Jameson BA, Korngold R.

J Biol Chem. 1996 Sep 13;271(37):22635-40.

13.

Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 of domain 3 in the heavy chain of high molecular weight kininogen.

Kunapuli SP, Bradford HN, Jameson BA, DeLa Cadena RA, Rick L, Wassell RP, Colman RW.

J Biol Chem. 1996 May 10;271(19):11228-35.

14.

Leu271-Glu292 in kininogens blocks thrombin-induced aggregation.

Colman RW, Bradford HN, Kunapuli SP, DeLa Cadena RA, Rick L, Jameson BA, Wassell RP.

Immunopharmacology. 1996 May;32(1-3):80-1. Review. No abstract available.

PMID:
8796272
15.

Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor.

McDonnell JM, Beavil AJ, Mackay GA, Jameson BA, Korngold R, Gould HJ, Sutton BJ.

Nat Struct Biol. 1996 May;3(5):419-26.

PMID:
8612071
16.

Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat.

Häyry P, Myllärniemi M, Aavik E, Alatalo S, Aho P, Yilmaz S, Räisänen-Sokolowski A, Cozzone G, Jameson BA, Baserga R.

FASEB J. 1995 Oct;9(13):1336-44.

PMID:
7557024
17.
18.

Binding of high-molecular-mass kininogen to the Apple 1 domain of factor XI is mediated in part by Val64 and Ile77.

Seaman FS, Baglia FA, Gurr JA, Jameson BA, Walsh PN.

Biochem J. 1994 Dec 15;304 ( Pt 3):715-21.

19.

High-affinity, specific factor IXa binding to platelets is mediated in part by residues 3-11.

Ahmad SS, Rawala-Sheikh R, Cheung WF, Jameson BA, Stafford DW, Walsh PN.

Biochemistry. 1994 Oct 11;33(40):12048-55.

PMID:
7918424
20.

A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis.

Jameson BA, McDonnell JM, Marini JC, Korngold R.

Nature. 1994 Apr 21;368(6473):744-6.

PMID:
8152486
21.

Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.

Bradford HN, Jameson BA, Adam AA, Wassell RP, Colman RW.

J Biol Chem. 1993 Dec 15;268(35):26546-51.

22.

Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach.

Moore JP, Jameson BA, Sattentau QJ, Willey R, Sodroski J.

Philos Trans R Soc Lond B Biol Sci. 1993 Oct 29;342(1299):83-8.

PMID:
7904352
23.
24.

Factor XI and platelets: activation and regulation.

Walsh PN, Baglia FA, Jameson BA.

Thromb Haemost. 1993 Jul 1;70(1):75-9. Review. No abstract available.

PMID:
8236119
25.

Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1.

Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R.

Cancer Res. 1993 Mar 1;53(5):1102-6.

26.
27.
28.

Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1.

Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R.

Cancer Res. 1992 Dec 1;52(23):6447-51.

29.

Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins?

Schulz TF, Jameson BA, Lopalco L, Siccardi AG, Weiss RA, Moore JP.

AIDS Res Hum Retroviruses. 1992 Sep;8(9):1571-80.

PMID:
1457203
30.

Direct involvement of the CDR3-like domain of CD4 in T helper cell activation.

McDonnell JM, Blank KJ, Rao PE, Jameson BA.

J Immunol. 1992 Sep 1;149(5):1626-30.

PMID:
1387146
32.
33.
35.

The gp120-CD4 interface: structural, immunological and pathological considerations.

Kieber-Emmons T, Jameson BA, Morrow WJ.

Biochim Biophys Acta. 1989 Dec 27;989(3):281-300. Review. No abstract available.

PMID:
2559777
36.

Modelling in peptide design.

Jameson BA.

Nature. 1989 Oct 5;341(6241):465-6. No abstract available.

PMID:
2797170
37.

Identification of a novel retroviral gene unique to human immunodeficiency virus type 2 and simian immunodeficiency virus SIVMAC.

Kappes JC, Morrow CD, Lee SW, Jameson BA, Kent SB, Hood LE, Shaw GM, Hahn BH.

J Virol. 1988 Sep;62(9):3501-5.

38.

Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein.

Jameson BA, Rao PE, Kong LI, Hahn BH, Shaw GM, Hood LE, Kent SB.

Science. 1988 Jun 3;240(4857):1335-9.

PMID:
2453925
39.

An integrated family of amino acid sequence analysis programs.

Wolf H, Modrow S, Motz M, Jameson BA, Hermann G, Förtsch B.

Comput Appl Biosci. 1988 Mar;4(1):187-91.

PMID:
3382992
40.

The antigenic index: a novel algorithm for predicting antigenic determinants.

Jameson BA, Wolf H.

Comput Appl Biosci. 1988 Mar;4(1):181-6.

PMID:
2454713
41.

Hepatitis B virus proteins eliciting protective immunity.

Neurath AR, Jameson BA, Huima T.

Microbiol Sci. 1987 Feb;4(2):45-51. Review.

PMID:
3153169
42.

Antigenic variation and resistance to neutralization in poliovirus type 1.

Diamond DC, Jameson BA, Bonin J, Kohara M, Abe S, Itoh H, Komatsu T, Arita M, Kuge S, Nomoto A, et al.

Science. 1985 Sep 13;229(4718):1090-3.

PMID:
2412292
43.
44.

The immune response to poliovirus-specific synthetic peptides: effects of adjuvants and test animal species.

Emini EA, Schleif WA, Jameson BA, Wimmer E.

J Virol Methods. 1985 Feb;10(2):163-70.

PMID:
2984231
45.
46.

Peptide priming of a poliovirus neutralizing antibody response.

Wimmer E, Emini EA, Jameson BA.

Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S505-9.

PMID:
6330847
47.

Poliovirus antigenic sites and vaccines.

Wimmer E, Jameson BA, Emini EA.

Nature. 1984 Mar 1-7;308(5954):19. No abstract available.

PMID:
6199673
48.

Neutralization antigenic sites of poliovirus and peptide induction of neutralizing antibodies.

Emini EA, Wimmer E, Jameson BA, Bonin J, Diamond D.

Ann Sclavo Collana Monogr. 1984;1(2):139-46. No abstract available.

PMID:
6085885
49.

Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides.

Emini EA, Jameson BA, Wimmer E.

Nature. 1983 Aug 25-31;304(5928):699-703.

PMID:
6310403
50.

Supplemental Content

Loading ...
Support Center